CTRI/2026/07/113498进行中（未招募）3 期
Comparison of efficacy and adverse effects of methotrexate 0.3 mg per kg per week and tofacitinib 5 mg twice daily versus methotrexate 0.3 mg per kg per week and cyclosporine 4 mg per kg ideal body weight in two divided doses in chronic plaque psoriasis a randomised - NIL
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of age 18-60 years
- •Weight 50-75 kg
- •Given their consent to participate in the study
- •PASI more than 10
- •Cumulative methotrexate dose less than 1.5 gm
- •Not taking systemic therapy for 1 month prior to enrolment
- •Not applying topical therapy for 2 weeks prior to enrolment
- •Not receiving phototherapy
排除标准
- •Pregnancy or lactation
- •History of alcoholism
- •Taking hepatotoxic or nephrotoxic drugs
- •Haemoglobin less than 8 gm per dL
- •TLC less than 4000 cells per mm3
- •Platelet count less than 1 lakh per mm3
- •Lymphocytes less than 1500 per mm3
- •Raised SGPT or SGOT more than twice the normal limit at baseline or more than thrice the normal limit at follow up
- •Raised Total bilirubin more than 1.2 or 30 percent increase from baseline during treatment period
- •Serum creatinine values of more than 1.4 mg per dl at baseline or more than 30 percent increase in baseline at two consecutive visits.
- •Any uncontrolled significant medical condition
- •Peptic ulcers
- •Any evidence of active or latent tuberculosis
- •Long standing deep vein thrombosis
- •Family or personal history of cancer or carcinoma in-situ
研究者
相似试验
进行中（未招募）
3 期
NN9838-7910: A research study to look at how two different doses of CagriSema and one dose of semaglutide help people living with obesity with or without type 2 diabetes lose weightNutritional, Metabolic, EndocrinePACTR202607641626021Novo Nordisk120
招募中
不适用
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial DiseasejRCT20312505701,205
招募中
1 期
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies2024-511453-22-00Kumquat Biosciences Inc.112
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
进行中（未招募）
2 期
To Study effect of Gayatriyadi kasayam with Chandraprabha vati in the management of Diabetic patientsCTRI/2026/07/114062Sonu Yadav37